With 13 years of experience and an outstanding record of performance, the HIV Prevention Trials Network (HPTN) Laboratory Center (LC) is optimally positioned to support the HPTN in 2013 and beyond. As part of the HPTN Leadership Group, the LC will help shape the network's scientific agenda. The HPTN LC will oversee laboratory activities at study sites;perform Quality Control/Quality Assurance (QA/QC) and specialized testing for HPTN protocols;evaluate and validate assays for use in HPTN protocols;develop novel assays to achieve study objectives;and perform ancillary studies related to HIV prevention. The HPTN LC has comprehensive QA/QC, Virology, and Pharmacology Cores, with Support Laboratories in other key areas (Sexually Transmitted Diseases, Microbiology, Immunology, and Toxicology). The HPTN LC has extensive experience supporting HIV prevention trials in the United States, South America, Asia, and Africa and has led efforts to harmonize laboratory procedures across networks and in other groups. The HPTN LC has supported HPTN protocols evaluating behavioral, biomedical, and structural interventions for HIV prevention, often delivered in combination in a wide range of settings and non-traditional venues. This includes observational, Phase I, Phase II and Phase III studies, with interventions delivered to HIV uninfected individuals, HIV-infected individuals, couples, cohorts, and communities. HPTN study populations include adolescents, women, men who have sex with men, serodiscordant couples, injection drug users, and individuals with acute HIV infection, with some trials enrolling >50,000 participants.
The Specific Aims of the HPTN LC are:
Aim 1 : To provide leadership, expertise, and laboratory support to the HPTN;
Aim 2 : To support site laboratories and ensure the quality of HPTN laboratory results;
Aim 3 : To advance HIV prevention science through assay development and biomedical research. A strong and effective LC is particularly important in the HPTN because of the vast international scope, diversity, and complexity of HIV prevention trials. This award will enable the HPTN to continue its mission to identify effective strategies for HIV prevention that will help end the HIV/AIDS epidemic.

Public Health Relevance

The goal of HIV Prevention Trials Network (HPTN) is to identify effective strategies for HIV prevention. The HPTN Laboratory Center (LC) is part of the HPTN leadership group. HPTN LC investigators will oversee laboratory testing performed at study sites, analyze samples collected in HPTN studies, develop novel laboratory assays, and perform laboratory-related research relevant to HIV prevention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI068613-08
Application #
8554494
Study Section
Special Emphasis Panel (ZAI1-TS-A (S1))
Program Officer
Gilbreath, Michael J
Project Start
2006-06-01
Project End
2020-11-30
Budget Start
2014-01-01
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$3,209,530
Indirect Cost
$795,872
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hickson, DeMarc A; Mena, Leandro A; Wilton, Leo et al. (2017) Sexual Networks, Dyadic Characteristics, and HIV Acquisition and Transmission Behaviors Among Black Men Who Have Sex With Men in 6 US Cities. Am J Epidemiol 185:786-800
Jennings, Larissa; Pettifor, Audrey; Hamilton, Erica et al. (2017) Economic Resources and HIV Preventive Behaviors Among School-Enrolled Young Women in Rural South Africa (HPTN 068). AIDS Behav 21:665-677
Shanaube, Kwame; Schaap, Ab; Floyd, Sian et al. (2017) What works - reaching universal HIV testing: lessons from HPTN 071 (PopART) trial in Zambia. AIDS 31:1555-1564
Margolick, Joseph B; Bream, Jay H; Martínez-Maza, Otoniel et al. (2017) Frailty and Circulating Markers of Inflammation in HIV+ and HIV- Men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 74:407-417
Schlusser, Katherine E; Konikoff, Jacob; Kirkpatrick, Allison R et al. (2017) Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence. AIDS Res Hum Retroviruses 33:555-557
MacPhail, Catherine; Khoza, Nomhle; Selin, Amanda et al. (2017) Cash transfers for HIV prevention: what do young women spend it on? Mixed methods findings from HPTN 068. BMC Public Health 18:10
Palumbo, Philip J; Wilson, Ethan A; Piwowar-Manning, Estelle et al. (2017) Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One 12:e0177281
Chen, Iris; Zhang, Yinfeng; Cummings, Vanessa et al. (2017) Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States. AIDS Res Hum Retroviruses 33:745-748
Mahiané, Severin Guy; Laeyendecker, Oliver (2017) Segmented polynomials for incidence rate estimation from prevalence data. Stat Med 36:334-344
Sivay, Mariya V; Li, Maoji; Piwowar-Manning, Estelle et al. (2017) Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr 75:271-279

Showing the most recent 10 out of 186 publications